Biontech SE at JPMorgan Healthcare Conference Transcript
Great. Good afternoon. Welcome, everyone. My name's Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference today with Biontech.
First, you're going to hear a presentation from the company, and then we're going to go into some Q&A. (Event Instructions)
So with that out of the way, I'm pleased to introduce Biontech's CEO, Ugur Sahin.
Hello, everyone. It's a pleasure to be here. I would like to welcome everyone here and online. These are the typical disclaimers. And I would like to start with the -- can we just change what is on the monitor? This was anticipated to be -- okay, it's good.
So let me start with the status quo that we have here. While Biontech has grown and evolved, our vision has remained the same, namely translating science into survival. From the current situation, from today's perspective, we have so far delivered together with our partner Pfizer 5 billion doses of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
